Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR1797275

— · cohortSC

bb9b0ed3-f871-55e7-9433-71e2665dd590

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSC
subtype
cohortSC
age_years
55

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.360
  • MYC_TARGETS_V1+0.340
  • E2F_TARGETS+0.290
  • G2M_CHECKPOINT+0.270
  • MITOTIC_SPINDLE+0.270
  • UNFOLDED_PROTEIN_RESPONSE+0.240
  • PROTEIN_SECRETION+0.220
  • INTERFERON_ALPHA_RESPONSE+0.210
  • MTORC1_SIGNALING+0.170
  • DNA_REPAIR+0.140

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
  • NOTCH_SIGNALING-0.410
  • APICAL_SURFACE-0.340
  • TNFA_SIGNALING_VIA_NFKB-0.320
  • INFLAMMATORY_RESPONSE-0.290
  • ANGIOGENESIS-0.280
  • COAGULATION-0.280
  • CHOLESTEROL_HOMEOSTASIS-0.270
  • MYOGENESIS-0.250
  • ESTROGEN_RESPONSE_EARLY-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1797282
lung-landscapes@6
—cohortSC0.876
2004589d9-7eb6-46cb-b822-20cd1939aa7e
melanoma-umap@29
——0.850
3BS_8GW1TMV2
brain-umap@2
medulloblastoma—0.849
4BS_TW8DQH8J
brain-umap@2
medulloblastoma—0.848
5TCGA-44-3917-01A-01R-A278-07
lung-landscapes@6
—cohortMD20.847
6SRR1797285
lung-landscapes@6
—cohortSC0.845
7GSM6454749
breast-umap@18
—F0.840
8d01f4531-b145-414b-bc1c-0f1a148b771e
melanoma-umap@29
——0.833
988328
medullo-epn-umap@date-based
EPNSupratentorial EPN0.829
10SRR1797279
lung-landscapes@6
—cohortSC0.827

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.360Cobimetinib— uncovered
MYC_TARGETS_V10.340Inavolisib— uncovered
E2F_TARGETS0.290Inavolisib— uncovered
G2M_CHECKPOINT0.270Inavolisib— uncovered
MITOTIC_SPINDLE0.270Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.240Idelalisib— uncovered
PROTEIN_SECRETION0.220Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.210Inavolisib— uncovered
MTORC1_SIGNALING0.170Inavolisib— uncovered
DNA_REPAIR0.140Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.120Remibrutinib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered
MYC_TARGETS_V20.090Idelalisib— uncovered
BILE_ACID_METABOLISM0.080Inavolisib— uncovered
ANDROGEN_RESPONSE0.070Inavolisib— uncovered
PEROXISOME0.070Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.050Idelalisib— uncovered
FATTY_ACID_METABOLISM0.030Inavolisib— uncovered